Five things for pharma marketers to know: Friday, February 5, 2016

Five things for pharma marketers to know: Friday, February 5, 2016

Johnson & Johnson collaborates with biotech on diabetes stem-cell treatment; the FDA warms up to Remicade biosimilar; Woodcock warns about biosimilar backlog

Ascension Health ups Ragone to chief marcomms officer

Ascension Health ups Ragone to chief marcomms officer

The Ketchum veteran joined the nonprofit healthcare system in mid-2014.

House Oversight committee upbraids Turing, Valeant execs

House Oversight committee upbraids Turing, Valeant execs

A House lawmaker called pricing strategies used by Turing and Valeant "repulsive."

Burcin departs Havas network for Klick Health in senior-staffing push

Burcin departs Havas network for Klick Health in senior-staffing push

Burcin's charge is to keep momentum going at the indie agency, known for placing ice-cream carts outside of rival agencies and other recruiting tactics.

Five things for pharma marketers to know: Thursday, February 4, 2016

Five things for pharma marketers to know: Thursday, February 4, 2016

Valeant to push for changes to financial-assistance rules; House to hold hearing on drug-pricing practices; FDA committee says Lundbeck can add information to leaflet

McCann Torre Lazur names new president

McCann Torre Lazur names new president

After Bill McEllen's departure, the company promoted Mark Willmann to lead the agency.

Johnson & Johnson comms leader stepping down

Johnson & Johnson comms leader stepping down

FitzPatrick is departing the company as it evaluates its 150 agency partnerships.

Five things for pharma marketers to know: Wednesday, February 3, 2016

Five things for pharma marketers to know: Wednesday, February 3, 2016

Seven potential blockbusters set to launch in 2016; Amarin case may lead to 'misleading' marketing; Valeant, Turing raised prices to meet preset targets

Orphan drug sales expected to grow 12% by 2020

Orphan drug sales expected to grow 12% by 2020

Click for an infographic to learn more about orphan drugs, rare diseases and the top-selling drugs in the category.

Five things for pharma marketers to know: Tuesday, February 2, 2016

Five things for pharma marketers to know: Tuesday, February 2, 2016

Gleevec generics hit shelves; four OxyContin patents are invalidated; Sanofi axes 600 positions

Email Newsletters